Trial Profile
A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2022
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors RVL Pharmaceuticals
- 28 Apr 2017 Status changed from recruiting to suspended.
- 19 Aug 2016 New trial record